Survival for glucagonoma

Glucagonoma is a type of neuroendocrine tumour (NET) of the pancreas. Survival for glucagonomas depends on many factors. So you should only use these statistics as a guide.

Doctors usually work out the outlook for a certain disease by looking at large groups of people. Because glucagonomas are rare tumours, the survival of this disease is harder to estimate than for other, more common cancers.

These are general statistics based on small groups of people. Remember, they can’t tell you what will happen in your individual case. Your doctor can give you more information about your own outlook (prognosis).

You can also talk about this with the Cancer Research UK nurses on freephone 0808 800 4040, from 9am to 5pm, Monday to Friday.

What affects survival

Survival depends on many factors. It depends on the stage and grade of the tumour when it was diagnosed. The stage describes the size of the tumour and whether it has spread. The grade means how abnormal the cells look under a microscope.

Another factor is how well you are overall. 

Survival for glucagonomas

There are no UK survival statistics for the different types of NETs. The statistics below are from an international study. Please be aware that due to differences in health care systems, data collection and the population, these figures may not be a true picture of survival in the UK.

The sample we describe below had surgery for glucagonoma. They also all had diabetic-dermatogenic syndrome (DDS). DDS is common in people with glucaganoma. It is can cause symptoms such as a rash, weight loss and high blood sugars.

  • around 65 out of 100 people (around 65%) with glucaganoma and DDS survive their disease for 10 years or more

This is for everyone included in the sample. You tend to do better if your cancer hasn’t spread.

  • about 100 out of every 100 people (100%) with glucagonoma and DDS syndrome that has not spread to other parts of the body survive their disease for 10 years or more
  • more than 50 out of every 100 people (more than 50%) with glucagonoma and DDS that has spread to other parts of the body survive their disease for 10 years or more

Survival for NETs of the pancreas

1 year survival

The information below is for 1 year overall survival for pancreatic neuroendocrine neoplasms (NENs) in the UK.

Around 80 in 100 people (around 80%) survive for 1 year or more.

5 year survival

There are no UK-wide 5 year survival statistics available for pancreatic NENs. The statistics below are from a European study. Please be aware that these figures may not be a true picture of survival in the UK. This is due to differences in health care systems, data collection and the population,

Around 40 out of 100 people (around 40%) survive their cancer for 5 years or more after diagnosis.

About these statistics

The terms 1 year, 5 year and 10 year survival don't mean that you will only live for 1, 5 or 10 years.

The Office for National Statistics (ONS) and researchers collect information. They watch what happens to people with cancer in the years after their diagnosis. 5 or 10 years is a common time point to measure survival. But some people live much longer than this.

5 or 10 year survival is the number of people who have not died from their cancer within 5 or 10 years after diagnosis.

What next?

You might want to read our information about treatment for glucagonomas. 

  • Functioning and nonfunctioning pNENs
    K Daskalakis 
    Current Opinion in Endocrine and Metabolic Research, 2021. Vol 18, June 2021, Pages 284-290

  • Glucagonomas/diabetic-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases
    Jun Soja and Yasuko Yakuwa
    Journal of Hepatobiliary Pancreatic Surgery, 1998. Vol 5, Pages 312-319

  • Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015
    T Genus and others
    British Journal of Cancer (2019) Volume 121, pages 966–972

  • Neuroendocrine Tumours: Diagnosis and Management
    S Yalcin and K Oberg
    Springer, 2015

  • Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
    T Halfdanarson and others
    Annals of Oncology, 2008. Vol 19, Pages 1727-1733

  • ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes
    R T Jensen and others
    Neuroendocrinology, 2012. Vol 95, Pages 98-119

  • Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project
    J Maartaen Van de Zwan and others
    European Journal of Cancer Volume 49, Issue 11 July 2013, Pages 2565-2578

Last reviewed: 
23 Jun 2022
Next review due: 
23 Jun 2025

Related links